Trial Profile
A Randomized Pilot Study of Treatment for Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Immunoglobulins; Rituximab
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 16 Oct 2019 Status changed from recruiting to discontinued.
- 12 Apr 2018 Status changed from not yet recruiting to recruiting.
- 29 Dec 2017 New trial record